Conference Coverage

Crohn’s disease remission rates ‘remarkably higher’ with vedolizumab


 

AT ECCO 2023

COPENHAGEN – A study of 260 patients with Crohn’s disease finds that vedolizumab led to significantly better clinical remission rates as compared with patients who were treated with anti–tumor necrosis factor (TNF) therapy.

The study was presented at the annual congress of the European Crohn’s and Colitis Organization by Wolfgang Mohl, MD, of the Center for Gastroenterology in Saarbrucken, Germany, who suggested this biologic, which is a monoclonal antibody, could possibly be used as a first-line treatment instead of as a second or third choice. Currently, TNF inhibitors are generally prescribed first.

“Compared to previous research clinical trials, this prospective 2-year real-world study comparing vedolizumab with anti-TNF showed that, in biologic-naive Crohn’s disease patients, remission rates at 2 years with vedolizumab were remarkably higher than with anti-TNF [therapy],” Dr. Mohl and colleagues wrote in the study abstract.

“Now we know vedolizumab is a good first-line drug and that patients can stay on it for a long time,” he said in an interview. “These data also suggest that we are wrong in thinking TNF inhibitors should be standard. I don’t think this belief holds true anymore.”

The study included 63 biologic-naive patients who were treated with vedolizumab and 197 patients who were treated with anti-TNF agents adalimumab (58.4%) and infliximab (41.6%).

After 2 years, approximately 83% of patients who were treated with vedolizumab were still receiving treatment, but only 56% of patients who received anti-TNF therapy were still undergoing therapy with either adalimumab or infliximab. After 2 years of treatment, 64.2% of patients who were treated with vedolizumab were in clinical remission, compared with 44.7% of patients who were treated with anti-TNF therapy. And, 62.5% of patients who were treated with vedolizumab were not receiving steroid treatment, compared with 41.6% of patients in the anti-TNF therapy group. This, Dr. Mohl said, was a statistically significant difference (P < .05).

“It is clinically relevant to achieve remission without steroids because this is hard to obtain,” he said. “Patients really don’t want to have to take steroids because they can experience lots of side effects including osteoporosis. It’s good to be in remission, but to be in steroid-free remission is so much better.”

Vedolizumab is a relatively new drug, compared with infliximab and adalimumab, which were approved by the Food and Drug Administration in 1998 and 2008, respectively. “We wanted real-world data to help us understand the pattern of outcomes outside of the clinical trial environment,” Dr. Mohl said.

From 45 treatment centers across Germany, researchers prospectively enrolled 1,200 biologic-naive and biologic-experienced patients with either Crohn’s disease or ulcerative colitis between 2017 and 2020 into the VEDOIBD study. This analysis was limited to 260 patients with Crohn’s disease.

In addition to a higher proportion of patients on vedolizumab continuing on treatment, compared with patients on anti–TNF inhibitor therapy, there was a significantly higher clinical remission rate with vedolizumab (64.2%), compared with anti-TNFi therapy (44.7%) after 2 years (P < .05). Researchers used a statistical method to determine the effect of 2-year maintenance in only those patients who responded to a 3-month induction, and they found a significantly better response in terms of clinical remission in patients on vedolizumab (88.6%), compared with anti-TNF inhibitors (45.8%) (P = .0001), and likewise in steroid-free remission with 86.8% for vedolizumab, compared with 44.1% for anti-TNF inhibitors (P < .001).

Dr. Mohl described his experience with vedolizumab in clinical practice. “Vedolizumab may take a little longer to work but then we don’t lose patients due to side effects, which we see more often with anti-TNF therapy,” he said, adding that around 60% of patients experience side effects but around 10% actually stop anti-TNF because of side effects.

“We often lose patients because they develop antidrug antibodies, but also due to escape mechanisms, as well as dermatological side effects including psoriasis which is really annoying for patients. We also find that anti-TNF drugs just stop working after 12-18 months, and then we need to use steroids which patients dislike,” he said.

Andreas Stallmach, MD, director of gastroenterology, Friedrich Schiller University Jena (Germany), described the findings as important.

“I see this as a really important real-world data study and to summarize, vedolizumab in Crohn’s disease is better than expected. The main explanation for the difference is due to loss of response in the anti-TNF group and this could be explained by the development of autoantibodies against anti-TNF drugs. Now, vedolizumab could be a first-line treatment in patients with Crohn’s disease, especially patients with risk factors for, or history of infections, of comorbidities,” he said.

As a modern monoclonal antibody, vedolizumab uses fewer autoantibodies, compared with infliximab, which is much older, Dr. Stallmach said. “If we combine infliximab with an immunosuppressant agent, such as azathioprine, then we can prevent autoantibody development and increase the efficacy and adherence rate, but with this comes the increased risk of infections and malignancies.”

Dr. Mohl receives research support from companies involved in making biologics for inflammatory bowel disease. Dr. Stallmach is on the advisory boards of most companies that make biologics, including Takeda, which sponsored this study.

* This article was updated March 10, 2023.

Recommended Reading

AGA clinical practice update: Telemedicine in gastroenterology
MDedge Internal Medicine
Celiac disease appears to double COVID-19 hospitalization risk
MDedge Internal Medicine
Cannabis tied to lower IBD mortality, hospital costs
MDedge Internal Medicine
IBD: More patients on vedolizumab vs. anti-TNFs at 2 years
MDedge Internal Medicine
DNA panels could predict endoscopic response to biologics in Crohn’s disease
MDedge Internal Medicine
Posttransplant NASH patients fare worse with older donor livers
MDedge Internal Medicine
Pediatric IBD patients wrestle with lingering gut pain
MDedge Internal Medicine
Ileocecal resection possible first-line option in early Crohn’s disease
MDedge Internal Medicine
EoE: One-food elimination works as well as six-food elimination
MDedge Internal Medicine
What do high BUN/Cr ratios mean?
MDedge Internal Medicine